Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06803342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2026 to Feb 2027
    • Study completion date: Dec 2026 to Apr 2027
    • Site details revised at 4 of 4 sites
    v8
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Aug 2026 to Dec 2026v6 Show 6 more changesShow less
    • Study completion date: Apr 2027 to Dec 2026
    • Interventions: Placebo (Biological), cAD3-Sudan Vaccine (Biological) to Placebo (Biological), cAd3-Sudan Vaccine (Biological)
    • Secondary endpoints revised (10)
    • Primary endpoint revised
    • Study description revised
    • Site details revised at 3 of 4 sites
  4. Study sites: 6 to 4v5
  5. Study sites: 7 to 6
    • Eligibility criteria expanded, about 1 word
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Secondary endpoints: details revised at 5 of 10 entriesv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoint revised
    • Study sites: 4 to 7
    • Start date changed from estimate of Jun 2025 to Jun 26, 2025
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoints revised (10)
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Trial Details
NCT Number NCT06803342
Lead Sponsor Albert B. Sabin Vaccine Institute
Collaborators: Biomedical Advanced Research and Development Authority
Conditions
(from sponsor)		 Ebola Sudan Virus Disease
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov